Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker

Teresa Órpez-Zafra, Jose Pavía, Isaac Hurtado-Guerrero, Maria J. Pinto-Medel, Jose Luis Rodriguez Bada, Patricia Urbaneja, Margarita Suardíaz, Luisa M. Villar, Manuel Comabella, Xavier Montalban, Jose C. Alvarez-Cermeño, Laura Leyva, Óscar Fernández, Begoña Oliver-Martos

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

© SAGE Publications. Background: The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in untreated multiple sclerosis (MS) than in healthy controls (HCs). Objective: To assess sIFNAR2 levels in a new cohort of MS patients and HCs, as well as in patients with clinically isolated syndrome (CIS) and with other inflammatory neurological disorders (OIND) and to assess its ability as a diagnostic biomarker. Methods: The cross-sectional study included 148 MS (84 treatment naive and 64 treated), 87 CIS, 42 OIND, and 96 HCs. Longitudinal study included 94 MS pretreatment and after 1 year of therapy with IFN-β, glatiramer acetate (GA), or natalizumab. sIFNAR2 serum levels were measured by a quantitative ELISA developed and validated in our laboratory. Results: Naive MS and CIS patients showed significantly lower sIFNAR2 levels than HCs and OIND patients. The sensitivity and specificity to discriminate between MS and OIND, for a sIFNAR2 cutoff value of 122.02 ng/mL, were 70.1%, and 79.4%, respectively. sIFNAR2 increased significantly in IFN-β-treated patients during the first year of therapy in contrast to GA- and natalizumab-treated patients who showed non-significant changes. Conclusion: The results suggest that sIFNAR2 could be a potential diagnostic biomarker for MS.
Original languageEnglish
Pages (from-to)937-945
JournalMultiple Sclerosis
Volume23
Issue number7
DOIs
Publication statusPublished - 1 Jun 2017

Keywords

  • biomarker
  • diagnosis
  • Multiple sclerosis
  • soluble interferon beta receptor

Fingerprint Dive into the research topics of 'Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker'. Together they form a unique fingerprint.

  • Cite this

    Órpez-Zafra, T., Pavía, J., Hurtado-Guerrero, I., Pinto-Medel, M. J., Rodriguez Bada, J. L., Urbaneja, P., Suardíaz, M., Villar, L. M., Comabella, M., Montalban, X., Alvarez-Cermeño, J. C., Leyva, L., Fernández, Ó., & Oliver-Martos, B. (2017). Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Multiple Sclerosis, 23(7), 937-945. https://doi.org/10.1177/1352458516667564